Cargando…

Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies

BACKGROUND: The continual reassessment method (CRM) identifies the maximum tolerated dose (MTD) more efficiently and identifies the true MTD more frequently compared to standard methods such as the 3 + 3 method. An initial estimate of the dose-toxicity relationship (prior skeleton) is required, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	James, G. D., Symeonides, S., Marshall, J., Young, J., Clack, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786936/ https://www.ncbi.nlm.nih.gov/pubmed/33402104 http://dx.doi.org/10.1186/s12885-020-07703-6

Ejemplares similares

Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 data
por: James, Gareth D., et al.
Publicado: (2016)

A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method
por: North, Bernard, et al.
Publicado: (2019)

A Comprehensive Comparison of the Continual Reassessment Method to the Standard 3 + 3 Dose Escalation Scheme in Phase I Dose-Finding Studies
por: Iasonos, Alexia, et al.
Publicado: (2008)

Dose Finding by the Continual Reassessment Method
por: Cheung, Ying
Publicado: (2011)

Phase I dose-escalation oncology trials with sequential multiple schedules
por: Günhan, Burak Kürsad, et al.
Publicado: (2021)

Dose Escalation Methods in Phase I Cancer Clinical Trials
por: Le Tourneau, Christophe, et al.
Publicado: (2009)

Extending the Continual Reassessment Method to accommodate step‐up dosing in Phase I trials
por: Braun, Thomas M., et al.
Publicado: (2022)

Exposure driven dose escalation design with overdose control: Concept and first real life experience in an oncology phase I trial
por: Micallef, Sandrine, et al.
Publicado: (2022)

How to design a dose-finding study using the continual reassessment method
por: Wheeler, Graham M., et al.
Publicado: (2019)

A novel model of the continual reassessment method in Phase I trial
por: Zhang, Weijia, et al.
Publicado: (2023)

Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise
por: Dai, Wei Fang, et al.
Publicado: (2021)

Reassessment of the lung dose limits for radioembolization
por: Kappadath, S. Cheenu, et al.
Publicado: (2021)

Local continual reassessment methods for dose finding and optimization in drug-combination trials
por: Zhang, Jingyi, et al.
Publicado: (2023)

Practical implementation of the partial ordering continual reassessment method in a Phase I combination‐schedule dose‐finding trial
por: Mozgunov, Pavel, et al.
Publicado: (2022)

Clinical Factors Associated With Dose Escalation of Solifenacin for the Treatment of Overactive Bladder in Real Life Practice
por: Chun, Ji-Youn, et al.
Publicado: (2014)

A nonparametric Bayesian continual reassessment method in single-agent dose-finding studies
por: Tang, Niansheng, et al.
Publicado: (2018)

Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
por: Wheeler, Graham M.
Publicado: (2016)

Real de-escalation or escalation in disguise?
por: Banys-Paluchowski, Maggie, et al.
Publicado: (2023)

Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer
por: Saunders, M P, et al.
Publicado: (2004)

GUIP1: a R package for dose escalation strategies in phase I cancer clinical trials
por: Dinart, D., et al.
Publicado: (2020)

Analysis of Various Factors Associated With Opioid Dose Escalation in Patients With Cancer Pain
por: Sakamoto, Ryo, et al.
Publicado: (2022)

Designing phase I oncology dose escalation using dose–exposure–toxicity models as a complementary approach to model‐based dose–toxicity models
por: Pantoja, Kristyn, et al.
Publicado: (2022)

Clinical Outcomes Following Dose-Escalated Proton Therapy for Skull-Base Chordoma
por: Holtzman, Adam L., et al.
Publicado: (2021)

Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer
por: Scholz, Mark, et al.
Publicado: (2017)

Dose escalation for stereotactic arrhythmia radioablation of recurrent ventricular tachyarrhythmia - a phase II clinical trial
por: Kovacs, Boldizsar, et al.
Publicado: (2023)

A web tool for designing and conducting phase I trials using the continual reassessment method
por: Wages, Nolan A., et al.
Publicado: (2018)

Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
por: Coombes, R. C., et al.
Publicado: (2023)

Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial
por: Melichar, B, et al.
Publicado: (2011)

Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial
por: Atmaca, A, et al.
Publicado: (2007)

Mesenchymal Stem Cells for Severe Intraventricular Hemorrhage in Preterm Infants: Phase I Dose‐Escalation Clinical Trial
por: Ahn, So Yoon, et al.
Publicado: (2018)

Dose escalations in phase I studies: Feasibility of interpreting blinded pharmacodynamic data
por: Hassing, Gerardus J., et al.
Publicado: (2022)

Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial
por: Maitland, Michael L., et al.
Publicado: (2018)

Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open
por: Sands, Bruce E., et al.
Publicado: (2019)

Reassessment of HIV-1 Acute Phase Infectivity: Accounting for Heterogeneity and Study Design with Simulated Cohorts
por: Bellan, Steve E., et al.
Publicado: (2015)

Ustekinumab dose escalation improves clinical responses in refractory Crohn’s disease
por: Haider, Syedreza A., et al.
Publicado: (2020)

Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial
por: Heilig, C.E., et al.
Publicado: (2021)

Reassessing the risk from rabies: A continuing threat to the UK?
por: Banyard, Ashley C., et al.
Publicado: (2010)

A placebo-controlled Bayesian dose finding design based on continuous reassessment method with application to stroke research
por: Cai, Chunyan, et al.
Publicado: (2017)

3488 A comparison between the Rolling 6 and 3+3 dose escalation study designs for phase 1 clinical trials
por: Minard, Charles Gene, et al.
Publicado: (2019)

Frequency and Clinical Outcomes of CYP2C19 Genotype-Guided Escalation and De-escalation of Antiplatelet Therapy in a Real-World Clinical Setting
por: Martin, Jesse, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9n65m2iqej7es0o71d94glk7u8